Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00809718 · ClinicalTrials.gov registry record · Phase 1
The Effect of Rifapentine on Raltegravir
A Phase 1 study, sponsored by The University of Texas Health Science Center at San Antonio.
- Completed
- Registry status
- Phase 1
- Development phase
- 27
- Enrollment target
NCT00809718 is a Phase 1 study that has completed, run by The University of Texas Health Science Center at San Antonio. The registered enrollment target is 27 participants.
The verdict
NCT00809718, a Phase 1 study, has completed, sponsored by The University of Texas Health Science Center at San Antonio.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 27 participants
- Enrollment target
Study Summary
The aim of this study is to study the effect of rifapentine on plasma concentrations of raltegravir.
Interventions
- DRUG Raltegravir and rifapentine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 27 participants |
| Start Date | 2009-02 |
| Est. Completion | 2011-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00809718
The ClinicalTrials.gov registry entry for NCT00809718 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 27 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is The University of Texas Health Science Center at San Antonio, which has 378 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Raltegravir and rifapentine is the first listed.
NCT00809718 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00809718 about?
NCT00809718 is a clinical study titled "The Effect of Rifapentine on Raltegravir". The aim of this study is to study the effect of rifapentine on plasma concentrations of raltegravir.
What is the current status of trial NCT00809718?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 27 participants. The study started on 2009-02. Estimated completion is 2011-08.
What interventions are being tested in trial NCT00809718?
The interventions under investigation include: Raltegravir and rifapentine (DRUG).
Who is sponsoring clinical trial NCT00809718?
This trial is sponsored by The University of Texas Health Science Center at San Antonio, which has 378 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.